This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Altering phosphorylation in cancer through PP2A modifiers
Cancer Cell International Open Access 06 January 2024
-
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
Oncogene Open Access 27 October 2023
-
SET/PP2A signaling regulates macrophage positioning in hypoxic tumor regions by amplifying chemotactic responses
Experimental & Molecular Medicine Open Access 12 October 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Perrotti D, Neviani P . Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 2013; 14: e229–e238.
Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD . PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011; 25: 606–614.
Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012; 97: 543–550.
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144–4157.
Estella Hermoso-de Mendoza A, Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Odero MD et al. Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia. J Biomed Nanotechnol 2014; in press.
Agarwal A, Mackenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 2014; 20: 2092–2103.
Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP . Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011; 30: 2504–2513.
Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 2013; 122: 1923–1934.
Saito S, Miyaji-Yamaguchi M, Shimoyama T, Nagata K . Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun 1999; 259: 471–475.
Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I et al. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett 2011; 585: 2653–2659.
Yu G, Yan T, Feng Y, Liu X, Xia Y, Luo H et al. Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging 2013; 34: 1748–1758.
Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013; 5: 105–121.
Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 2011; 186: 2535–2542.
Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013; 122: 3034–3044.
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408–2421.
Acknowledgements
We thank Dr Bachs for the GST-SET FL and Dr Ye for the GST-SET 1–77, 1–127, 1–177 and 1–227 fragments. This study was supported by Ministerio de Ciencia e Innovación (PI11/02443), Departamento Salud del Gobierno de Navarra (78/2012), ISCIII-RTICC (RD12/0036/0063) and Fundación para la Investigación Médica Aplicada (Spain).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
DJC and MPV are shareholders (>5%) and employees of Oncotide Pharmaceuticals, Inc. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Pippa, R., Dominguez, A., Christensen, D. et al. Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia 28, 1915–1918 (2014). https://doi.org/10.1038/leu.2014.141
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.141
This article is cited by
-
Altering phosphorylation in cancer through PP2A modifiers
Cancer Cell International (2024)
-
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
Oncogene (2023)
-
SET/PP2A signaling regulates macrophage positioning in hypoxic tumor regions by amplifying chemotactic responses
Experimental & Molecular Medicine (2022)
-
Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia
Leukemia (2021)
-
Targeting of SET/I2PP2A oncoprotein inhibits Gli1 transcription revealing a new modulator of Hedgehog signaling
Scientific Reports (2021)